Advanced search
Publication Cover
Acta Cardiologica Volume 62, 2007 - Issue 2
Submit an article Journal homepage
9
Views
0
CrossRef citations to date
0
Altmetric
Review Article

A new era for oral anticoagulation? Old and new anticoagulant drugs

Peter VerhammeVascular Medicine and Coagulation Disorders, Centre for Molecular and Vascular Biology, Gasthuisberg University Hospital, Leuven, Belgium.Correspondence[email protected]
&
Raymond VerhaegheVascular Medicine and Coagulation Disorders, Centre for Molecular and Vascular Biology, Gasthuisberg University Hospital, Leuven, Belgium.
Pages 189-198 | Received 26 Sep 2006, Accepted 12 Feb 2007, Published online: 23 May 2017

References

  • Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 265S-286S.
  • Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Euro-pean Society of Cardiology Committee for Practice Guide-lines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J2006; 27: 1979–2030.
  • Weitz JI, Middeldorp S, Geerts W, Heit JA. Thrombophilia and new anticoagulant drugs. Hematology (Am Soc Hema-tol Educ Program) 2004; 424–38.
  • Anse11 J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrom-botic and Thrombolytic Therapy. Chest 2004; 126: 204S-2233.
  • Hirsh J. Heparin. N Engl J Med 1991; 324: 1565–74.
  • Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 274–84.
  • Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helter-brand JD, Ely EW, Fisher CJ, Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709.
  • Petitou M, Duchaussoy P, Herbert JM, Duc G, El HM, Branellec JF, Donat F, Necciari J, Cariou R, Bouthier J, Garrigou E. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28: 393–402.
  • Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fonda-parinux vs. enoxaparin for the prevention of venous throm-boembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833–40.
  • Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous throm-bosis: a randomized trial. Ann Intern Med 2004; 140: 867–73.
  • Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Novella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695–702.
  • Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295: 1519–30.
  • Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxa-parin in acute coronary syndromes. N Engl J Med 2006; 354: 1464–76.
  • Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479–86.
  • Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kalebo P. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374–81.
  • Wallis RB. Hirudins: from leeches to man. Semin Thromb Hemost 1996; 22: 185–96.
  • Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, Andersson M, Freij A. The direct thrombin inhibitor mela-gatran followed by oral ximelagatran compared with enoxa-parin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490–6.
  • Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstrom T, Berkowitz SD, Nystrom P, Thorsen M, Ginsberg JS. Ximelagatran vs. low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681–9.
  • Olsson SB. Stroke prevention with the oral direct throm-bin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691–8.
  • Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A. Ximelagatran vs. warfarin for stroke preven-tion in patients with nonvalvular atrial fibrillation: a ran-domized trial. JAMA 2005; 293: 690–8.
  • Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P A new oral direct thmmbin inhibitor, dabi-gatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replace-ment: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103–11.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.